Jul 2024 $5 M No. 4 $2 to $10 million 8
Transposon Therapeutics, Inc.: Raise no. 4, Jul 2024 × Investors in this round 8 investors had bought by the notice of Jul 15, 2024: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $20 M offered; $15 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Dennis Taylor Podlesak · Executive Officer, Director Eckard R. Weber, MD · Executive Officer, Director Lynne R. Rollins · Executive Officer Brent R. Ahrens · Director Brian Taylor Slingsby, MD, PHD, MPH · Director Daniel R. Hetu, MD, MBA · Director John R. Pacifico · Director Keith A. Katkin · Director William R. Harrington, MD, MBA · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Dennis G. Podlesak, Chief Executive Officer. Newest notice filed Jul 15, 2024. Read the notice at the SEC .
debt, options SEC Dec 2022 $5 M No. 3 $2 to $10 million 8
Transposon Therapeutics, Inc.: Raise no. 3, Dec 2022 × Investors in this round 8 investors had bought by the notice of Jan 12, 2023: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $20 M offered; $15 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eckard R. Weber, MD · Executive Officer, Director Lynne R. Rollins · Executive Officer Brent R. Ahrens · Director Brian Taylor Slingsby, MD, PHD, MPH · Director Daniel R. Hetu, MD, MBA · Director Dennis Taylor Podlesak · Director John R. Pacifico · Director Keith A. Katkin · Director William R. Harrington, MD, MBA · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Lynne R. Rollins, Chief Financial Officer. Newest notice filed Jan 12, 2023. Read the notice at the SEC .
equity, options SEC Nov 2020 $45 M No. 2 $10 to $50 million 10
Transposon Therapeutics, Inc.: Raise no. 2, Nov 2020 × Investors in this round 10 investors had bought by the notice of Dec 9, 2020: 10 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $45 M of $45 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Series A Preferred Stock and the underlying Common Stock issuable upon its conversion. Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Dennis Podlesak · Executive Officer, Director Eckard Weber, M.D. · Executive Officer, Director Lynne R. Rollins · Executive Officer Brent R. Ahrens · Director John R. Pacifico · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Lynne R Rollins, Chief Financial Officer. Newest notice filed Dec 9, 2020. Read the notice at the SEC .
equity, options SEC Apr 2020 $4 M No. 1 $2 to $10 million 4
Transposon Therapeutics, Inc.: Raise no. 1, Apr 2020 × Investors in this round 4 investors had bought by the notice of May 6, 2020: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $7 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold equity, debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eckard Weber, M.D. · Executive Officer, Director Lynne Rollins · Executive Officer Brent Ahrens · Director Dennis Podlesak · Director John Pacifico · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Lynne Rollins, CFO and Treasurer. Newest notice filed May 6, 2020. Read the notice at the SEC .
equity, debt, options SEC